A Phase 3 interventional study of Pozelimab + Cemdisiran and Cemdisiran in Generalized Myasthenia Gravis, sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 116 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 144 studies in Myasthenia Gravis with a site in United States — 53 open to participants now, 73 under way, 25 of them phase 3. Myasthenia Gravis · United States.
Among the 144 studies in Myasthenia Gravis with a site in United States, this one has the largest enrollment of the 108 interventional ones that give a count, is one of 13 that started in 2021, is one of 45 in phase 3, reaches primary completion later than 7 of the 72 other live ones, and was the 68th registered.
330 studies on the registry are indexed under Myasthenia Gravis; 144 are open to participants now.
Browse Myasthenia Gravis studies →53 of the 144 studies in Myasthenia Gravis with a site in United States are open now. Recruiting first, the newest first:
TG Therapeutics, Inc. · Sites in United States
Ages 18+
UCB Biopharma SRL · Sites in United States, China, France and 4 more countries
Ages 18+
George Washington University · Sites in United States
Ages 18+
Amgen · Sites in United States, Argentina, Brazil and 5 more countries
Ages 2–17
argenx · Sites in United States, Belgium, Greece and 4 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
144 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 38 · Phase 3 51 · Phase 4 3
First in 1995; this study’s year is marked. 13 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 288 is above the median of 44 across 217 interventional studies indexed under Myasthenia Gravis.
Median enrollment 56 across the 108 interventional studies, 226 across the 36 observational. Of the 64 that completed or were terminated, 41 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
96 of 144 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 1 study filed under Myasthenia Gravis — fewer than ten, so there is no comparison to draw.
18 of the studies in Myasthenia Gravis with a site in United States that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06607627Phase 3Alexion Pharmaceuticals, Inc.PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis | 2026-12-15 |
| NCT06799247Phase 3Cartesian TherapeuticsInvestigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis | 2026-12-30 |
| NCT04833894Phase 3argenxEvaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis | 2027-03 |
| NCT06456580Phase 3Vor BiopharmaA Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | 2027-03 |
| NCT06517758Phase 3Novartis PharmaceuticalsA Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. | 2027-04-30 |
Add all 18 to your calendar (.ics) → With an account.
Among the 144 studies in Myasthenia Gravis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is researching the experimental drugs called pozelimab and cemdisiran, and cemdisiran monotherapy. The study is focused on patients with generalized Myasthenia Gravis (gMG). Myasthenia gravis is a disease that causes weakness and fatigue in muscles in the body because the nerves and muscles are not communicating properly.
The aim of the study is to see how effective pozelimab and cemdisiran are when used in combination and when pozelimab and cemdisiran are used alone for patients with gMG.
The study is looking at several other research questions, including:
DBTP- Double Blind Treatment Period (24 weeks) ETP - Extension Treatment Period (28 weeks) OLTP- Open Label Treatment Period (68 weeks) FUP-Off treatment Follow Up Period (52 weeks)
The criteria were revised on the registry on Oct 28, 2026. See what changed
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol-defined Inclusion/ Exclusion Criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo in DBTP; Re-randomized to Combination or Cemdisiran in ETP. Participants who received combination therapy during ETP and have not yet reached OLTP be reallocated to cemdisiran at the start of OLTP. In OLTP, participants on combination therapy who have not reached week 108 will switch to cemdisiran, while those who have reached week 108 will continue combination therapy
Drug: Pozelimab + Cemdisiran · Drug: Cemdisiran · Other: Placebo
Combination regimen in DBTP and ETP. Participants who have not yet reached OLTP will be reallocated to cemdisiran at the start of OLTP. Participants who are in OLTP and have not reached week 108 will switch to cemdisiran, while those who have reached week 108 will continue combination therapy.
Drug: Pozelimab + Cemdisiran · Drug: Cemdisiran
Cemdisiran throughout the study
Drug: Cemdisiran
Pozelimab monotherapy in DBTP followed by combination in ETP. Participants who have not yet reached OLTP will be reallocated to cemdisiran at the start of OLTP. Participants who are in OLTP and have not reached week 108 will switch to cemdisiran, while those who have reached week 108 will continue combination therapy.
Drug: Pozelimab + Cemdisiran · Drug: Cemdisiran · Drug: Pozelimab
Drug pages: Pozelimab · Cemdisiran
Subcutaneous administration as described in the protocol
SC administration as described in the protocol
Also known as: ALN-CC5
SC administration as described in the protocol
SC administration as described in the protocol
Also known as: REGN3918
Change in Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score
The total MG-ADL score ranges from 0 to 24 points, with higher scores indicating greater functional impairment and disability
Time frame: From baseline to week 24
Change from baseline in Quantitative Myasthenia Gravis (QMG) score
QMG total scores range from 0 to 39, with higher scores representing greater impairment
Time frame: Week 24
Achievement of a ≥3-point reduction (improvement) in MG-ADL total score
Time frame: From baseline to week 24
Achievement of a ≥5-point reduction (improvement) in QMG total score
Time frame: From baseline to week 24
Achievement of a consistent response on the MG-ADL
A participant with a ≥2-point reduction (improvement) in MG-ADL total score on 2 or more consecutive assessments spanning 4 or more weeks during the DBTP
Time frame: From baseline to week 24
Achievement of Minimal Symptom Expression (MSE)
Score of 0 to 1 on the MG-ADL
Time frame: Week 24
Change from baseline in the Myasthenia Gravis Composite (MGC) total score
MGC score ranges from 0 to 50, with higher score indicating higher impairment
Time frame: Week 24
Change from baseline in Myasthenia Gravis Quality of Life (MG-QOL15r) total score
Total score ranges from 0 to 30 points; a higher score represents greater impairment
Time frame: Week 24
Achievement of a ≥2-, 4-, 5-, 6-, 7-, 8-, 9-, or 10-point reduction on MG-ADL total score
Time frame: From baseline to week 24
Achievement of a ≥3-, 4-, 6-, 7-, 8-, 9-, or 10-point reduction on QMG
Time frame: From baseline to week 24
Incidence and severity of Treatment-Emergent Adverse Events (TEAEs) in participants treated with pozelimab + cemdisiran combination therapy, cemdisiran monotherapy or placebo
Time frame: Through week 24
Incidence and severity of Serious Adverse Events (SAEs) in participants treated with pozelimab + cemdisiran combination therapy, cemdisiran monotherapy or placebo
Time frame: Through week 24
Incidence and severity of Adverse Events of Special Interest (AESIs) in participants treated with pozelimab + cemdisiran combination therapy, cemdisiran monotherapy or placebo
Time frame: Through week 24
Concentrations of total pozelimab in serum
Time frame: Through study duration, approximately 172 weeks
Concentrations of total Complement component 5 (C5) in plasma
Time frame: Through study duration, approximately 172 weeks
Concentrations of cemdisiran and its metabolites in plasma
Time frame: Through study duration, approximately 172 weeks
Incidence of treatment-emergent Anti-Drug Antibodies (ADAs) to pozelimab over time
Time frame: Through study duration, approximately 172 weeks
Incidence of treatment-emergent ADAs to cemdisiran over time
Time frame: Through study duration, approximately 172 weeks
Change in total complement hemolysis activity assay (CH50) over time
Time frame: Through study duration, approximately 172 weeks
Percent change in CH50 over time
Time frame: Through study duration, approximately 172 weeks
Concentrations of cemdisiran and its metabolite in plasma
During the OLTP for the optional PK sub-study
Time frame: At week 60 and up to week 120
Concentrations of total C5 in plasma
During the OLTP for the optional PK sub-study
Time frame: At week 60 and up to week 120
Incidence of TEAEs
During the OLTP for the optional PK sub-study
Time frame: Through week 144
Severity of TEAEs
During the OLTP for the optional PK sub-study
Time frame: Through week 144
Incidence of SAEs
During the OLTP for the optional PK sub-study
Time frame: Through week 144
Severity of SAEs
During the OLTP for the optional PK sub-study
Time frame: Through week 144
Incidence of AESIs
During the OLTP for the optional PK sub-study
Time frame: Through week 144
Severity of AESIs
During the OLTP for the optional PK sub-study
Time frame: Through week 144
Showing the first 100 of 116 sites across 19 countries. Choose a country and city above to see the rest.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), the legal authority to share the data, and ensured the ability to protect participant privacy.
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
Ran from Dec 2021 to primary completion in Jul 2025, 42 months.
Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 42 months is above that.
Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pozelimab · Cemdisiran